Back to top
more

Karyopharm Therapeutics (KPTI)

(Delayed Data from NSDQ)

$1.28 USD

1.28
1,306,160

-0.10 (-7.25%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $1.27 -0.01 (-0.78%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for KPTI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Karyopharm Therapeutics Inc. [KPTI]

Reports for Purchase

Showing records 141 - 160 ( 386 total )

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 141

11/23/2020

Company Report

Pages: 8

Detailed Phase 3 SEAL Data Presented at CTOS 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 142

11/15/2020

Industry Report

Pages: 13

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 143

11/03/2020

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 144

11/03/2020

Company Report

Pages: 6

XPOVIO Notches Win in Liposarcoma, Steady Growth in Core Franchise

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 145

11/03/2020

Company Report

Pages: 8

3Q20 Results; Positive Phase 3 SEAL Study Results in Liposarcoma

Provider: H.C. Wainwright & Co., Inc.

Analyst: WRIGHT J

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 146

09/25/2020

Industry Report

Pages: 53

Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended September 18

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 147

09/22/2020

Industry Report

Pages: 14

ESMO 2020: Covered Companies Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 148

09/18/2020

Company Report

Pages: 8

Notable Xpovio Data in Solid Tumors at ESMO 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 149

08/05/2020

Company Report

Pages: 8

2Q20 Results; Xpovio PDUFA March 19, 2021 for Patients With Multiple Myeloma After at Least One Prior Line of Therapy

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 150

08/04/2020

Company Report

Pages: 7

2Q20 Earnings; PDUFA Teed Up for March 19

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 151

07/20/2020

Company Report

Pages: 7

Xpovio sNDA Accepted in Multiple Myeloma Patients After One Line of Therapy

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 152

07/17/2020

Daily Note

Pages: 53

Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended July 10

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 153

07/17/2020

Company Report

Pages: 7

CRADA With NCI Could Expand Xpovio Indications in the Future

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 154

07/15/2020

Daily Note

Pages: 5

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 155

07/14/2020

Company Report

Pages: 4

Management Provides 2Q20 Estimated Sales; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 156

07/14/2020

Daily Note

Pages: 6

Preannounced Q2:20 XPOVIO Sales Beat, Maintain Outlook

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 157

06/25/2020

Industry Report

Pages: 45

AACR II 2020 Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 158

06/23/2020

Daily Note

Pages: 5

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 159

06/23/2020

Company Report

Pages: 8

FDA Approves Xpovio as a Treatment for Relapsed or Refractory Diffuse Large B-Cell Lymphoma; PT to $41

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 160

06/22/2020

Industry Report

Pages: 58

Weekly Retail Sales Tracker for Hem. Malignancies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party